Article
Gastroenterology & Hepatology
Ruby Greywoode, Francesca Petralia, Thomas A. Ullman, Jean Frederic Colombel, Ryan C. Ungaro
Summary: Racial minority groups showed lower rates of clinical response, clinical remission, and endoscopic healing in golimumab induction and maintenance trials compared to White participants.
INFLAMMATORY BOWEL DISEASES
(2023)
Article
Gastroenterology & Hepatology
Marina Liso, Giulio Verna, Elisabetta Cavalcanti, Stefania De Santis, Raffaele Armentano, Angela Tafaro, Antonio Lippolis, Pietro Campiglia, Antonio Gasbarrini, Mauro Mastronardi, Theresa Torres Pizarro, Fabio Cominelli, Loris Riccardo Lopetuso, Marcello Chieppa
Summary: This study provides new insights and alternative approaches to treat ulcerative colitis (UC) patients. It suggests that anti-interleukin (IL)1 strategies, such as anakinra, may be a more effective therapeutic option for primary nonresponders to anti-tumor necrosis factor (TNF) therapy.
CELLULAR AND MOLECULAR GASTROENTEROLOGY AND HEPATOLOGY
(2022)
Article
Medicine, General & Internal
Naohiko Kinoshita, Kazuki Kakimoto, Hikaru Shimizu, Koji Nishida, Keijiro Numa, Yuka Kawasaki, Hideki Tawa, Kei Nakazawa, Ryoji Koshiba, Yuki Hirata, Naokuni Sakiyama, Eiko Koubayashi, Toshihisa Takeuchi, Takako Miyazaki, Kazuhide Higuchi, Shiro Nakamura, Hiroki Nishikawa
Summary: This study evaluated the role of serum biomarkers in predicting the efficacy of golimumab in bio-naive patients with UC. The results suggest that IL-13 may be a potential biomarker to predict the response to golimumab treatment.
JOURNAL OF CLINICAL MEDICINE
(2022)
Article
Medicine, General & Internal
Marouf Alhalabi, Kemal Alaa Eddin, Khaled Cheha, Ahmad Abbas
Summary: The study demonstrated the effectiveness of subcutaneous golimumab in inducing and maintaining remission in a pediatric patient with steroid-refractory ulcerative colitis flare. This suggests a potential role for golimumab in the treatment of pediatric ulcerative colitis in the future.
Article
Gastroenterology & Hepatology
Kathrin Perrig, Niklas Krupka, Sebastian Bruno Ulrich Jordi, Jean-Benoit Rossel, Luc Biedermann, Thomas Greuter, Philipp Schreiner, Stephan R. Vavricka, Pascal Juillerat, Emanuel Burri, Dorothee Zimmermann, Michel H. Maillard, Michael Christian Sulz, Stephan Brand, Gerhard Rogler, Benjamin Misselwitz
Summary: This study summarizes the experience of golimumab in a real-world setting in Switzerland. The results show that golimumab treatment is associated with a sustained reduction of symptoms and clinical response in approximately 30% of patients.
THERAPEUTIC ADVANCES IN GASTROENTEROLOGY
(2022)
Article
Pharmacology & Pharmacy
Riccardo Capecchi, Paola Migliorini, Federico Zanzi, Simona Maltinti, Ilaria Puxeddu, Nicola de Bortoli, Massimo Bellini, Francesco Costa, Santino Marchi, Lorenzo Bertani
Summary: The study demonstrated a correlation between Ig glycosylation and disease activity in UC patients, suggesting a potential role for lectin-selected Ig in predicting therapeutic effectiveness. If confirmed, Ig glycosylation could serve as a biomarker in UC.
FRONTIERS IN PHARMACOLOGY
(2021)
Article
Gastroenterology & Hepatology
Daniela Pugliese, Giuseppe Privitera, Francesca Rogai, Angela Variola, Anna Viola, Lucrezia Laterza, Antonino C. Privitera, Mariangela Allocca, Fabrizio Bossa, Maria Cappello, Marco Daperno, Greta Lorenzon, Silvia Mazzuoli, Mariabeatrice Principi, Renato Sablich, Luisa Moser, Antonio Ferronato, Sara Traini, Gherardo Tapete, Giorgia Bodini, Maria Di Girolamo, Laurino Grossi, Giammarco Mocci, Chiara Ricci, Simone Saibeni, Stefano Festa, Rocco Spagnuolo, Claudio C. Cortelezzi, Filippo Mocciaro, Fernando Rizzello, Alessandro Armuzzi
Summary: This study investigated the long-term outcomes of patients with ulcerative colitis on golimumab therapy. Results showed that being biological-naive and able to discontinue steroids at Weeks 8 and 14 were associated with longer persistence on golimumab therapy. Maintaining continuous clinical response also led to a lower likelihood of golimumab discontinuation.
UNITED EUROPEAN GASTROENTEROLOGY JOURNAL
(2021)
Article
Gastroenterology & Hepatology
Lujain Maasfeh, Anetta Hartlova, Stefan Isaksson, Johanna Sundin, Georgios Mavroudis, Otto Savolainen, Hans Strid, Lena Ohman, Maria K. Magnusson
Summary: Fecal luminal factors from healthy donors can down-regulate signaling pathways in macrophages and influence their function, while those from UC patients in remission have a weaker effect on macrophages. Metabolomic analysis revealed differential fecal metabolite composition between healthy individuals and UC patients in remission. This suggests that UC patients in remission may lack the necessary signals to condition macrophages towards a hyporesponsive and tolerogenic phenotype, making them vulnerable to relapse.
CELLULAR AND MOLECULAR GASTROENTEROLOGY AND HEPATOLOGY
(2021)
Article
Gastroenterology & Hepatology
Kengo Kanayama, Jun Kato, Wataru Shiratori, Ariki Nagashima, Yuki Ohta, Takashi Taida, Keiko Saito, Chihiro Goto, Satsuki Takahashi, Ryosuke Horio, Akane Kurosugi, Tsubasa Ishikawa, Tatsuya Kaneko, Naoki Akizue, Kenichiro Okimoto, Tomoaki Matsumura, Naoya Kato
Summary: This study found that selecting subsequent treatment based on the response to initial anti-tumor necrosis factor (TNF)alpha antibody (ATA) is feasible in refractory ulcerative colitis (UC) patients. Non-ATA may be suitable as subsequent biologics for UC patients regardless of the efficacy of the first ATA.
JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY
(2022)
Article
Gastroenterology & Hepatology
Sun-Ho Lee, Margaret Walshe, Eun Hye Oh, Sung Wook Hwang, Sang Hyoung Park, Dong-Hoon Yang, Jeong-Sik Byeon, Seung-Jae Myung, Suk-Kyun Yang, Tomer Greener, Adam Weizman, Mark S. Silverberg, Byong Duk Ye
Summary: The study suggests that changes in serum albumin levels within the first 2 weeks of anti-TNF treatment can predict primary nonresponse, endoscopic outcomes, time to colectomy, and anti-TNF failure in patients with UC. Early access to this biomarker may help identify patients at risk of treatment failure and guide early optimization of anti-TNF therapy.
INFLAMMATORY BOWEL DISEASES
(2021)
Article
Gastroenterology & Hepatology
Delphine Ley, Ariane Leroyer, Claire Dupont, Helene Sarter, Valerie Bertrand, Claire Spyckerelle, Nathalie Guillon, Pauline Wils, Guillaume Savoye, Dominique Turck, Corinne Gower-Rousseau, Mathurin Fumery, Epimad Grp
Summary: This study evaluated the impact of immunosuppressants and antitumor necrosis factor on long-term outcomes of pediatric-onset ulcerative colitis in a large population-based cohort. The results showed a significant decline in the risk of colectomy in pediatric-onset ulcerative colitis patients with an increased use of immunosuppressants and anti-TNF. However, the risk of disease extension and flare-related hospitalization increased.
AMERICAN JOURNAL OF GASTROENTEROLOGY
(2023)
Article
Chemistry, Medicinal
Dong Zhang, Siwei Duan, Zhangyou He, Zeming Zhu, Zhiping Li, Qincheng Yi, Tiantian Cai, Juanjuan Li, Nan Chen, Shaoju Guo
Summary: This study explores the mechanism of Sijunzi Decoction (SJZ) in the treatment of ulcerative colitis (UC). The results indicate that SJZ treats UC by reducing the content of intestinal NETs, with primary targets on the NETs being IL1B and TNF and suppressing TNF signal. The practical components of SJZ may include ginsenoside Rh2, isoflavones, and formononetin.
DRUG DESIGN DEVELOPMENT AND THERAPY
(2023)
Article
Gastroenterology & Hepatology
Sebastian Stefanovic, Iris Detrez, Griet Compernolle, Els Brouwers, Nejc Sever, Borut Stabuc, Natasa Smrekar, Tina Kurent, Gregor Novak, Matic Kozelj, Marc Ferrante, Ann Gils, David Drobne
Summary: The use of golimumab with the new EMA label in UC patients has increased the rate of achieving and maintaining endoscopic remission. However, dose optimization is crucial for maintaining endoscopic remission in patients weighing <80 kg.
EUROPEAN JOURNAL OF GASTROENTEROLOGY & HEPATOLOGY
(2021)
Article
Gastroenterology & Hepatology
Carlos Taxonera, Maria Jesus Fernandez-Acenero, David Olivares, Marta Calvo, Begona Casis, Fernando Bermejo, Pilar Lopez Serrano, Marisa Iborra, Francisco Mesonero, Maia Bosca Watts, Cristina Diaz del Arco, Isabel Vera, Sonsoles Olivares, Alicia Algaba, Cristina Alba
Summary: This study investigated the association between golimumab trough concentrations during maintenance and outcomes such as endoscopic healing, histologic remission, and long-term persistence in UC patients. The results showed that golimumab concentrations were associated with favorable treatment outcomes.
ALIMENTARY PHARMACOLOGY & THERAPEUTICS
(2022)
Article
Biochemistry & Molecular Biology
Giulio Verna, Marina Liso, Elisabetta Cavalcanti, Raffaele Armentano, Alessandro Miraglia, Vladia Monsurro, Marcello Chieppa, Stefania De Santis
Summary: Colorectal cancer is a prime example of the link between inflammation and cancer. Targeting inflammatory mediators has shown to decrease the overall risk of colorectal cancer, although its chemopreventive potential remains debated. The role of tumor necrosis factor (TNF) in the development and progression of colorectal cancer is complex, with TNF having a dual effect.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
(2022)
Article
Dentistry, Oral Surgery & Medicine
Youssouf Sereme, Tabata Larissa S. Polvora, Nicolas Rochereau, Lucas Ribeiro Teixeira, Rodrigo Carvalho Santana, Stephane Paul, Benedito Antonio Lopes da Fonseca, Thomas Bourlet, Bruno Pozzetto, Alan Grupioni Lourenco, Ana Carolina F. Motta
Summary: This study found the presence of HIV-1 p24 antigen in the gingival tissue of HIV-1 and CP patients undergoing cART treatment, suggesting the existence of a reservoir for the virus in gingival tissue.
JOURNAL OF PERIODONTOLOGY
(2022)
Review
Gastroenterology & Hepatology
Mathilde Barrau, Manon Duprat, Pauline Veyrard, Quentin Tournier, Nicolas Williet, Jean Marc Phelip, Louis Waeckel, Adam S. Cheifetz, Konstantinos Papamichael, Xavier Roblin, Stephane Paul
Summary: This study systematically reviewed the feasibility of using drug-tolerant assays to monitor patients treated with anti-TNFs. Most ADAb detection methods are drug-sensitive and cannot be used close to drug administration, but several drug-tolerant techniques have been developed to overcome this limitation.
JOURNAL OF CROHNS & COLITIS
(2022)
Review
Immunology
Melyssa Yaugel-Novoa, Thomas Bourlet, Stephane Paul
Summary: Systemic and mucosal humoral immune responses play a crucial role in fighting the respiratory viral infection caused by the SARS-CoV-2 virus. Patient characteristics and disease severity can affect the dynamics of antibody infections, with higher antibody levels observed in severe cases. Vaccines have shown limited efficacy against new viral variants.
MUCOSAL IMMUNOLOGY
(2022)
Article
Biochemistry & Molecular Biology
Franck Zekre, Rolando Cimaz, Mireille Paul, Teresa Giani, Louis Waeckel, Anne-Emmanuelle Berger, Jean-Louis Stephan, Myriam Normand, Stephane Paul, Hubert Marotte
Summary: This study found that children with oligoarticular and ERA subsets in juvenile idiopathic arthritis (JIA) had higher IgG titers against P. gingivalis and P. intermedia, indicating the involvement of oral dysbiosis in the occurrence of JIA in these subgroups.
Article
Gastroenterology & Hepatology
Mathurin Fumery, Stephane Nancey, Jerome Filippi, Romain Altwegg, Xavier Hebuterne, Gilles Boshetti, Mathilde Barraud, Jonathan Meynier, Stephane Paul, Xavier Roblin
Summary: This study evaluated the effectiveness and safety of golimumab intensification and identified the best threshold of serum golimumab before drug intensification. The results showed that after golimumab intensification, 40% of patients experienced clinical response, 10% experienced clinical remission, 33% experienced endoscopic response, and 23% experienced endoscopic remission.
ALIMENTARY PHARMACOLOGY & THERAPEUTICS
(2023)
Review
Microbiology
Beatriz Miguelena Chamorro, Karelle De Luca, Gokul Swaminathan, Stephanie Longet, Egbert Mundt, Stephane Paul
Summary: Bordetella pertussis and Bordetella bronchiseptica are responsible for whooping cough in humans and chronic cough in dogs, respectively. Both can evade host immune responses, but this ability is more pronounced in B. bronchiseptica. Collaborative efforts between veterinary and human medical fields are essential to control these infections.
CLINICAL MICROBIOLOGY REVIEWS
(2023)
Article
Medicine, General & Internal
Xavier Roblin, Gerard Duru, Konstantinos Papamichael, Adam S. Cheifetz, Sandy Kwiatek, Anne-Emmanuelle Berger, Mathilde Barrau, Louis Waeckel, Stephane Nancey, Stephane Paul
Summary: Monitoring of anti-drug antibodies in patients on ustekinumab is not recommended due to low immunogenicity. This study aimed to investigate the relationship between anti-drug antibodies and loss of response to ustekinumab in patients with IBD. The results showed that ATU was an independent predictor of LOR to ustekinumab in IBD patients.
JOURNAL OF CLINICAL MEDICINE
(2023)
Article
Immunology
Carla Saade, Bruno Pozzetto, Melyssa Yaugel-Novoa, Guy Oriol, Laurence Josset, Bruno Lina, Stephane Paul, Antonin Bal, Sophie Trouillet-Assant
Summary: This study examines the humoral immune response in vaccinated patients who are simultaneously infected with Delta and Omicron BA.1 variants of SARS-CoV-2. The findings indicate that exposure to both Delta and BA.1 S proteins does not provide an additional immune advantage compared to exposure to BA.1 S protein alone.
Article
Immunology
Melyssa Yaugel-Novoa, Blandine Noailly, Fabienne Jospin, Anne-Emmanuelle Berger, Louis Waeckel, Elisabeth Botelho-Nevers, Stephanie Longet, Thomas Bourlet, Stephane Paul
Summary: The study found that prior immunization did not increase the risk of SARS-CoV-2 infection in COVID-19 patients and vaccinated individuals. There was no enhanced infection effect observed in serum samples from COVID-19 patients with any tested viral variants (Delta and Omicron). Some serum samples from vaccinated individuals showed a mild IgA-ADE effect with Omicron after the completion of the full vaccination scheme, but this effect disappeared.
Article
Immunology
Beatriz Miguelena Chamorro, Karelle De Luca, Gokul Swaminathan, Nicolas Rochereau, Jade Majorel, Herve Poulet, Blandine Chanut, Lauriane Piney, Egbert Mundt, Stephane Paul
Summary: In this study, the immune responses and protection offered by a canine mucosal vaccine against Bordetella bronchiseptica were investigated using a rat model. The results showed that mucosal vaccination can induce mucosal immune responses and provide protection against a Bb challenge.
Article
Biochemistry & Molecular Biology
Tristan Gabriel-Segard, Jessica Rontard, Louise Miny, Louise Dubuisson, Aurelie Batut, Delphine Debis, Melanie Gleyzes, Fabien Francois, Florian Larramendy, Alessandra Soriano, Thibault Honegger, Stephane Paul
Summary: This study presents a microfluidic technology that models bilateral neuro-immunological communication, confirming the communication between dendritic cells and neurons in inflammatory conditions such as IBD. The platform can be used for pharmacological compound screening and may help improve patient outcomes by blocking the gut-brain axis at a mucosal level.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
(2023)
Editorial Material
Gastroenterology & Hepatology
Xavier Roblin, Stephane Paul
JOURNAL OF CROHNS & COLITIS
(2023)
Editorial Material
Veterinary Sciences
Beatriz Miguelena Chamorro, Gokul Swaminathan, Egbert Mundt, Stephane Paul
Summary: Oral vaccines are convenient to administer and can activate mucosal immune responses. However, preclinical studies using gavage as a technique for oral vaccine administration have limitations. Alternative methods need to be explored.
Review
Medicine, General & Internal
Mathilde Barrau, Xavier Roblin, Leslie Andromaque, Aurore Rozieres, Mathias Faure, Stephane Paul, Stephane Nancey
Summary: Data on the long-term effects of in utero drug exposure on childhood development are lacking, but therapeutic drug monitoring during pregnancy can help limit fetal drug exposure. The levels and duration of drug exposure impact the outcomes.
JOURNAL OF CLINICAL MEDICINE
(2023)
Article
Gastroenterology & Hepatology
Xavier Roblin, Stephane Nancey, Konstantinos Papamichael, Gerard Duru, Mathurin Flamand, Sandy Kwiatek, Adam Cheifetz, Nicole Fabien, Mathilde Barrau, Stephane Paul
Summary: Higher concentrations of subcutaneous infliximab are associated with better therapeutic outcomes in patients with inflammatory bowel disease, especially deep remission.
JOURNAL OF CROHNS & COLITIS
(2023)